$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000162828015008551 Filed on November 09, 2015

Income Statement

Concept	2015 Q3	2014 Q3
Revenue	$58.00K	$57.00K
YoY Change	1.75%	29.55%
Cost Of Revenue	$173.5K	$0.00
YoY Change
Gross Profit	-$115.5K	$57.00K
YoY Change	-302.7%
Gross Profit Margin	-199.2%	100.0%
Selling, General & Admin	$3.747M	$2.007M
YoY Change	86.67%	-9.18%
% of Gross Profit		3521.36%
Research & Development	$2.547M	$1.990M
YoY Change	27.95%	117.41%
% of Gross Profit		3491.67%
Depreciation & Amortization	$100.0K	$60.00K
YoY Change	66.67%	20.0%
% of Gross Profit		105.26%
Operating Expenses	$6.467M	$3.997M
YoY Change	61.8%	336.61%
Operating Profit	-$6.410M	-$3.940M
YoY Change	62.67%	28.03%
Interest Expense	$352.7K	$389.9K
YoY Change	-9.53%	6124.99%
% of Operating Profit
Other Income/Expense, Net	-$8.130K	-$19.26K
YoY Change	-57.78%
Pretax Income	-$2.740M	-$5.380M
YoY Change	-49.07%	22.27%
Income Tax
% Of Pretax Income
Net Earnings	-$2.736M	-$5.375M
YoY Change	-49.1%	22.13%
Net Earnings / Revenue	-4716.95%	-9430.21%
Basic Earnings Per Share	-$0.10	-$0.28
Diluted Earnings Per Share	-$0.23	-$0.28
COMMON SHARES
Basic Shares Outstanding	28.56M shares	18.90M shares
Diluted Shares Outstanding	29.13M shares	18.90M shares

Balance Sheet

Concept	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$74.10M	$31.20M
YoY Change	137.5%	12.23%
Cash & Equivalents	$74.15M	$31.16M
Short-Term Investments
Other Short-Term Assets	$600.0K	$300.0K
YoY Change	100.0%	200.0%
Inventory
Prepaid Expenses
Receivables	$66.97K	$100.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$74.82M	$31.60M
YoY Change	136.76%	12.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.842M	$800.0K
YoY Change	130.28%	8.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$362.9K	$300.0K
YoY Change	20.98%	-27.17%
Total Long-Term Assets	$2.205M	$1.200M
YoY Change	83.76%	4.15%
TOTAL ASSETS
Total Short-Term Assets	$74.82M	$31.60M
Total Long-Term Assets	$2.205M	$1.200M
Total Assets	$77.02M	$32.80M
YoY Change	134.83%	12.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.100M	$500.0K
YoY Change	120.01%	214.5%
Accrued Expenses	$2.124M	$1.900M
YoY Change	11.79%	80.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.700M	$800.0K
YoY Change	362.5%	700.0%
Total Short-Term Liabilities	$6.969M	$3.100M
YoY Change	124.82%	127.82%
LONG-TERM LIABILITIES
Long-Term Debt	$11.50M	$14.00M
YoY Change	-17.86%	3400.0%
Other Long-Term Liabilities	$3.700M	$3.300M
YoY Change	12.12%	-47.62%
Total Long-Term Liabilities	$15.20M	$17.30M
YoY Change	-12.14%	158.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.969M	$3.100M
Total Long-Term Liabilities	$15.20M	$17.30M
Total Liabilities	$22.16M	$20.40M
YoY Change	8.65%	154.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.5M
YoY Change
Common Stock	$2.972K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.86M	$12.40M
YoY Change
Total Liabilities & Shareholders Equity	$77.02M	$32.80M
YoY Change	134.83%	12.52%

Cashflow Statement

Concept	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$2.736M	-$5.375M
YoY Change	-49.1%	22.13%
Depreciation, Depletion And Amortization	$100.0K	$60.00K
YoY Change	66.67%	20.0%
Cash From Operating Activities	-$5.130M	-$3.410M
YoY Change	50.44%	62.38%
INVESTING ACTIVITIES
Capital Expenditures	-$570.0K	-$110.0K
YoY Change	418.18%	-47.62%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$570.0K	-$110.0K
YoY Change	418.18%	-47.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	38.55M	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-5.130M	-3.410M
Cash From Investing Activities	-570.0K	-110.0K
Cash From Financing Activities	38.55M	0.000
Net Change In Cash	32.85M	-3.520M
YoY Change	-1033.24%	-118.06%
FREE CASH FLOW
Cash From Operating Activities	-$5.130M	-$3.410M
Capital Expenditures	-$570.0K	-$110.0K
Free Cash Flow	-$4.560M	-$3.300M
YoY Change	38.18%	74.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29722602	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2014Q3	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-2217142	USD
CY2015Q3	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-4017212	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-4017212	USD
	trov	Adjustments To Additional Paid In Capital Warrants Reclassified Amount AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount	0	USD
	trov	Adjustments To Additional Paid In Capital Warrants Reclassified Amount AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount	-435365	USD
CY2015Q2	trov	Area Of Land After Expansion AreaOfLandAfterExpansion	22600	sqft
	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	732378	shares
CY2014	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P3Y6M26D
	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P2Y9M13D
CY2014Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.85
CY2015Q3	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.86
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	3.77
	trov	Decrease In Derivative Liability Due To Exercise Of Warrants DecreaseInDerivativeLiabilityDueToExerciseOfWarrants	435365	USD
CY2014Q3	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	0	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	0	USD
CY2015Q3	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	6026	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	10712	USD
CY2015Q2	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	60000	USD
	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	30000	USD
CY2014Q3	trov	Original Value Of Warrants OriginalValueOfWarrants	235857	USD
CY2015Q3	trov	Original Value Of Warrants OriginalValueOfWarrants	0	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	16955	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	18180	USD
	trov	Term Of Extension For Interest Only Payment TermOfExtensionForInterestOnlyPayment	P6M
CY2014Q2	trov	Threshold Level Of Unrestricted Net Cash Proceeds Required To Extend Interest Only Payment Date ThresholdLevelOfUnrestrictedNetCashProceedsRequiredToExtendInterestOnlyPaymentDate	30000000	USD
CY2015Q2	trov	Threshold Level Of Unrestricted Net Cash Proceeds Required To Extend Interest Only Payment Date After Amendment ThresholdLevelOfUnrestrictedNetCashProceedsRequiredToExtendInterestOnlyPaymentDateAfterAmendment	21000000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	747799	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1100073	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56694	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2400	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	250600	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3006021	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	66967	USD
	us-gaap	Accretion Of Discount AccretionOfDiscount	28686	USD
	us-gaap	Accretion Of Discount AccretionOfDiscount	59665	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1841808	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2124080	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	533870	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	732866	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89739511	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156355718	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	405700	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1384959	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	923659	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2758846	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	96060	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	253028	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9585199	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11143202	shares
CY2015Q3	us-gaap	Area Of Land AreaOfLand	13000	sqft
CY2014Q4	us-gaap	Assets Assets	28896846	USD
CY2015Q3	us-gaap	Assets Assets	77022854	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	27719751	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	74817695	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25836937	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31163559	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27293798	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74149797	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6265620	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5533242	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18915794	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29722602	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18915794	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29722602	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	1891	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	2972	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	173537	USD
	us-gaap	Cost Of Revenue CostOfRevenue	429992	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	169599	USD
	us-gaap	Interest Expense InterestExpense	1133068	USD
	us-gaap	Interest Paid InterestPaid	248506	USD
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3675926	USD
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	24845	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-4562	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1466592	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4135310	USD
	us-gaap	Interest Paid InterestPaid	795375	USD
	us-gaap	Interest Expense InterestExpense	454082	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	352727	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1948546	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5756047	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	536844	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	616366	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16624	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	231672	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10452	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10273	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	195229	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	26238	USD
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	109992	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	568024	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	189341	shares
CY2014Q3	us-gaap	Interest Expense InterestExpense	389871	USD
CY2014Q3	us-gaap	Investment Income Net InvestmentIncomeNet	3470	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	7940	USD
CY2015Q3	us-gaap	Investment Income Net InvestmentIncomeNet	17368	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	32988	USD
CY2014Q4	us-gaap	Liabilities Liabilities	20547293	USD
CY2015Q3	us-gaap	Liabilities Liabilities	22164437	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28896846	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77022854	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4488155	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6969351	USD
CY2014Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	10000	USD
CY2015Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	13053117	USD
CY2015Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	11519160	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1898548	USD
CY2015Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	3745198	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	5326622	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	46855999	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14422759	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63423076	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-235623	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1256988	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8860514	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15310089	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5375217	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9642105	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2735829	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20090244	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	222931	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5381277	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9659060	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2741889	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20108424	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5381277	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11876202	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6759101	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24125636	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	3997427	USD
	us-gaap	Operating Expenses OperatingExpenses	10665243	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	6466879	USD
	us-gaap	Operating Expenses OperatingExpenses	18123154	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3940228	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10441463	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6409552	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17889511	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	336708	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	362946	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19255	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24845	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8130	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4617	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	235623	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1256988	USD
CY2014Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	16955	USD
CY2015Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18180	USD
CY2014Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2015Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	369259	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	600931	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	61215398	USD
	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	14938723	USD
	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	818251	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1389427	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1374257	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2575079	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	840387	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1842213	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	515964	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2014Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1990251	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4829945	USD
CY2015Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2546533	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7428349	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81391909	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101500333	USD
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	57199	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	213780	USD
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	51301	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	57199	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	223780	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	57327	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	233643	USD
CY2014Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	540584	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1699988	USD
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1798263	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4508766	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1384959	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2758847	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	8349553	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	54858417	USD
CY2014Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1029333	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1220655	USD
CY2015Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	4017212	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1105270	USD
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18902783	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19012775	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29128235	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25204307	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18902783	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18902783	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28560211	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25014966	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-008551-index-headers.html	Edgar Link	pending
0001628280-15-008551-index.html	Edgar Link	pending
0001628280-15-008551.txt	Edgar Link	pending
0001628280-15-008551-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-093015exhibit311.htm	Edgar Link	pending
trov-093015exhibit312.htm	Edgar Link	pending
trov-093015exhibit321.htm	Edgar Link	pending
trov-093015exhibit322.htm	Edgar Link	pending
trov-093015x10q.htm	Edgar Link	pending
trov-20150930.xml	Edgar Link	completed
trov-20150930.xsd	Edgar Link	pending
trov-20150930_cal.xml	Edgar Link	unprocessable
trov-20150930_def.xml	Edgar Link	unprocessable
trov-20150930_lab.xml	Edgar Link	unprocessable
trov-20150930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2015 Q3 Form 10-Q Financial Statement

#000162828015008551 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2015 Q3 Form 10-Q Financial Statement

#000162828015008551 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf